Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus University, Olof Palmes Allé 43, 8200, Aarhus, Denmark.
Centre for Observational Research, Amgen Ltd., Uxbridge, England.
Support Care Cancer. 2021 Aug;29(8):4501-4511. doi: 10.1007/s00520-020-05934-8. Epub 2021 Jan 18.
To describe use of bisphosphonates in newly diagnosed multiple myeloma patients in Denmark.
Using data from the Danish National Multiple Myeloma Registry, we conducted a population-based cohort study. Among patients newly diagnosed with multiple myeloma from 2005 to 2015, we examined use of bisphosphonates at first- and at progression/second-line anti-myeloma treatment overall, by patient characteristics, and myeloma complications.
Of 2947 patients starting first-line anti-myeloma treatment, 2207 patients (74.9%) received bisphosphonates. During a median follow-up of 27.6 (quartiles, 10.6-52.5) months, disease progression post-first-line treatment was recorded in 1546 patients, of whom 1065 (68.9%) were treated with bisphosphonates. Altogether, 80.9% of patients with and 37.6% of patients without myeloma bone disease were treated with bisphosphonates at first line and 73.0% and 42.7%, respectively, at progression/second line. Moreover, the proportion of patients treated with bisphosphonates decreased with increasing severity of renal impairment at first and at progression/second-line treatment.
The proportion of patients treated with bisphosphonates as part of first- and second-line anti-myeloma treatment increased with presence of myeloma bone disease and decreased by presence and severity of renal impairment. Overall, 25% of newly diagnosed multiple myeloma patients had no record of bisphosphonate treatment, potentially indicating an unmet need.
描述丹麦新诊断多发性骨髓瘤患者中双磷酸盐的使用情况。
使用丹麦国家多发性骨髓瘤登记处的数据，我们进行了一项基于人群的队列研究。在 2005 年至 2015 年间新诊断为多发性骨髓瘤的患者中，我们总体上检查了一线和进展/二线抗骨髓瘤治疗中双磷酸盐的使用情况，按患者特征和骨髓瘤并发症进行检查。
在开始一线抗骨髓瘤治疗的 2947 名患者中，2207 名（74.9%）接受了双磷酸盐治疗。在中位数为 27.6（四分位数间距，10.6-52.5）个月的随访期间，记录了 1546 名患者一线治疗后的疾病进展，其中 1065 名（68.9%）接受了双磷酸盐治疗。总体而言，80.9%有和 37.6%无骨髓瘤骨病的患者分别在一线和进展/二线治疗中接受了双磷酸盐治疗，而分别有 73.0%和 42.7%有和无肾功能损害的患者接受了双磷酸盐治疗。此外，在一线和进展/二线治疗中，接受双磷酸盐治疗的患者比例随着肾功能损害的严重程度的增加而降低。
作为一线和二线抗骨髓瘤治疗的一部分，接受双磷酸盐治疗的患者比例随着骨髓瘤骨病的存在而增加，随着肾功能损害的存在和严重程度而降低。总体而言，25%的新诊断多发性骨髓瘤患者没有双磷酸盐治疗记录，可能表明存在未满足的需求。
